SGOL2 is a novel prognostic marker and fosters disease progression via a MAD2-mediated pathway in hepatocellular carcinoma

Table 1 Correlation between SGOL2 expression and clinicopathological characteristics in Cohort 1

Variables	SGOL2 expression		Total	χ2	p-value
Variables	Low	High	Total	χ2	p-value
Age (year)
≤ 58	25	23	48	1.733	0.188
> 58	19	30	49
Null
Sex
Female	6	8	14	0.041	0.839
Male	38	45	83
*Grade*
1/2	40	33	73	10.236	*0.001*
3	4	20	24
*T stage*
T1/T2	33	29	62	4.289	*0.038*
T3/T4	11	24	35
*TNM stage*
Ι/II	33	29	62	4.289	*0.038*
III/IV	11	24	35
*Thrombus*
Negative	29	33	62	4.381	*0.036*
Positive	5	18	23
Null			12
Cirrhosis
Negative	9	11	20	0.002	0.965
Positive	32	40	72
Null			5
HBsAg
Negative	2	9	11		0.103*
Positive	39	42	81
Null			5
HBcAb
Negative	0	2	2		0.496*
Positive	38	41	79
Null			16
TB
Negative	23	36	59	0.531	0.466
Positive	15	17	32
Null			6
AFP
Negative	23	35	58	0.356	0.551
Positive	13	15	28
Null			11
ALB
Low	16	19	35	1.082	0.298
Normal/high	18	34	52
Null			10
GGT
Negative	3	5	8		0.693*
Positive	15	14	29
Null			60
ALT
Negative	16	30	46	2.859	0.091
Positive	25	23	48
Null			3
CD34
Negative	1	1	2		1.000*
Positive	26	36	62
Null			33
*CK19*
Negative	38	29	67	11.271	*0.001*
Positive	6	24	30
Null

ISSN: 2050-7771